Nanostics Inc


4550 - 10230 Jasper Ave
Phone number


Nanostics is a privately held Alberta-based company focused on the development and commercialization of novel, non-invasive diagnostic tests for cancer and other diseases. The technology at the core of Nanostics is an advanced liquid biopsy platform and state of the art machine learning algorithm for accurate diagnoses from a single drop of blood. The technology is applicable to a wide range of diseases including prostate, ovarian, pancreatic cancers, as well as cardiovascular, degenerative and neurological diseases. Nanostics’ lead product, ClarityDX Prostate, is the most accurate diagnostic test to diagnose aggressive prostate cancer, and is positioned to emerge as the world’s leading diagnostic tool for prostate cancer.



Board advisors

John D. Lewis, PhD, Founder and CEO

Dr. Lewis is the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta, Edmonton, Alberta. In addition to his academic work, Dr. Lewis is also the co-founded Innovascreen, Inc., a successful preclinical CRO in operation since 2005 and the founder and CEO of ENTOS pharmaceuticals, a start-up Drug Delivery Company incorporated in 2007. His research involves cancer diagnostics, non-invasive molecular imaging and targeting of angiogenesis and metastasis using multivalent nanoparticles. He trained at The Scripps Research Institute in La Jolla, CA, developing targeted molecular imaging technologies. Dr. Lewis holds a Ph.D. in biochemistry from the University of Victoria.

Dale Klein, President and CEO of Canada ICI Capital Corporation

Mr. Klein is the President and CEO of Canada ICI Capital Corporation, an established commercial mortgage brokerage firm specializing in full service brokerage operations. As the original founder of Canada ICI in 1993, Mr. Klein has grown the company to now have offices in Edmonton, Calgary, Winnipeg and Toronto, with annual origination volumes in excess of $2.5 billion. He has been actively involved in commercial real estate finance since 1986. With his extensive knowledge of both the debt and equity markets, he has personally arranged in excess of $8.0 billion of capital over his career. Mr. Klein is also the founder and a serving Board Members of Sector Mortgage Management Inc., a federally chartered mortgage investment corporation with assets in excess of $200 million. In addition, Mr. Klein is a member of the Real Estate Council of Alberta, a past Chair of the Sturgeon Industrial Heartland Advisory Committee and currently serves as Board Member and Audit Committee Chair of the Edmonton International Airport Authority as a Sturgeon Country Representative. He is a resident of Sturgeon County, AB.


Armen G. Aprikian, M.D., F.R.C.S.(C), Head of Urology and Interim Chief of Dept. Oncology at McGill University

Dr. Aprikian is the Head of Division of Urology, Department of Surgery, McGill University and serves as the Interim Chief of Department of Oncology, McGill University Health Centre Montreal, Quebec Canada. He joined the Department of Urology at the Montreal General Hospital as an Attending Surgeon. Dr. Aprikian serves as the Chairman of Medical Advisory Board at USHIFU, LLC. He has been a Board Observer of Bioniche Life Sciences Inc. since November 9, 2008. He served as a Director of Bioniche Life Sciences Inc. His awards and honours include the Everett C. Reid Award for Excellence in Teaching, which he received on three occasions, and the American Society of Clinical Oncology Investigator award. He was also named the McGill University William Dawson Scholar. He has been an invited lecturer locally, nationally and internationally and has held a number of Visiting Professorships. He earned his Medical Degree at the University of Sherbrooke (Sherbrooke, Quebec) Faculty of Medicine. Dr. Aprikian completed his residency at the McGill University Urology Residency Program (Montreal, Quebec).

Reg Joseph, MBA, Health Industry Executive for Edmonton Health City

Mr. Joseph has 15 years of experience in the biotechnology and high technology sectors. He has worked with large publicly traded firms, start-ups and the investment banking industry. As the former chief executive officer of Metabolomic Technologies Inc. (MTI), an Edmonton-based diagnostics firm, the company secured a multi-million-dollar commercial distribution deal for its flagship product PolpyDx™ in the U.S. The company also received the Frost & Sullivan Technology Leadership Award in 2014 and was declared the University of Alberta’s Start-up of the year in 2013. His prior experience also includes serving as the Vice President, Health at Alberta Innovates and as an equity research analyst with Boston-based Leerink Swann & Co., where he covered the life science tools sector. He also spent four years at US-based Invitrogen Corp (now Thermo Fisher) in a variety of roles including licensing, product development, acquisitions and integration. Reg has served in a variety of C-level and board positions with local medical technology-based start-ups. He currently serves on the Board of BioTalent Canada as Treasurer and Chair of Finance Committee. He also sits on BioAlberta’s policy committee and serves as President of the Board for the Seniors Association of Greater Edmonton (SAGE). He has a B.Sc. in Physiology and an MBA in Finance. . 

Melina Cimler, PhD, CEO and Founder of PandiaDx LLC

Dr. Melina Cimler has over 28 years of experience in the life science and FDA-regulated diagnostic industry, leading regulatory, quality systems, clinical affairs, research, and product development organizations, with a focus on precision medicine. Dr. Cimler served as Senior Vice President of Regulatory & Quality at Adaptive Biotechnologies until April 2018. She was previously Head of Global Quality and Vice President of Quality, Regulatory, Clinical, and Government Affairs at Illumina Inc. She defined and executed on the regulatory strategy resulting in the first next generation sequencing platform receiving FDA marketing authorization (Illumina’s MiSeqDx). Previously, she held leadership positions in quality, regulatory and government affairs as Senior Vice President at Beckman Coulter Inc. She also served in senior quality, clinical and regulatory roles at Abbott Molecular, Gen-Probe Inc., and C.R. Bard, and as head of Product Development at Epitope, Inc. (now OraSure Technologies). Dr. Cimler holds a Ph.D. in Pharmacology from the University of Washington.


Raised funding to date
Capital needed next round